Immunotherapy

 

The immune system is a system of cells and organs whose function is to defend an organism from foreign pathogens. With the ability to mount a response against virtually any foreign material and return to a quiescent state following neutralization of the threat, this fascinating organ system displays remarkable specificity and plasticity. To achieve this, there is a multifaceted balancing act between the many activators and suppressors that maintains homeostasis of perhaps the body’s most complex organ system.

Activation of the immune system involves a number of checkpoints in order to ensure proper activation. For instance, T cell activation requires binding of the T cell receptor to the MHC antigen, yet this interaction alone is not sufficient for producing a T cell response. Full T cell activation and inactivation requires the coordination of a multitude of co-stimulatory and inhibitory signals. For example, T cell activation can result from the combination of MHC:TCR and B7-1:CD28 interaction. In contrast, B7-1 binding to CTLA4 results in an inhibitory signal that prevents activation.

Given its diverse function and the fact that the immune system plays a role in virtually all human diseases, immunotherapy has become an important approach for the treatment of numerous diseases. Immunotherapy is defined as the treatment of disease by inducing, enhancing, or suppressing an immune response. This often involves targeting immunoreceptors, such as those discussed above, with small molecule inhibitors/activators or immune system components, including antibodies or antibody fragments (Fab). Immunotherapies have shown efficacy in the treatment of cancer, autoimmune diseases, inflammatory diseases, and more.

BPS Bioscience offers many purified, soluble immunoreceptors involved in key immunosignaling pathways. Additionally, we offer a number of assay kits that can be used to screen for inhibitors of protein-protein interaction, as well as neutralizing antibodies to serve as positive controls for inhibition.

References:

1.  Pardoll, D.M., Nat. Rev. Cancer. 2012; 12: 252-264.
2.  Lesterhuis, W.J., et al., Nat. Rev. Drug. Disc. 2011; 10: 591-600.

Immunotherapy Subcategories

Items 101 to 125 of 464 total

per page
Page:
  1. 3
  2. 4
  3. 5
  4. 6
  5. 7

Catalog#SizeProduct NamePrice
71168 50 µg CD155, His-tag, Biotin-labeled (Mouse) HiP™
$420
71173 100 µg CD160, His-tag (Human) HiP™
$310
71135 50 µg CD160, His-tag, Biotin-labeled (Human) HiP™
$420
79561-H 2 vials CD19 CHO Recombinant Cell Line (High Expression)
$5,500
79561-L 2 vials CD19 CHO Recombinant Cell Line (Low Expression)
$5,500
79561-M 2 vials CD19 CHO Recombinant Cell Line (Medium Expression)
$5,500
79472 100 μg CD19, Fc-Fusion (IgG1), Avi-Tag
$310
79475 50 μg CD19, Fc-Fusion (IgG1), Avi-Tag, Biotin-Labeled
$420
71264 100 μg CD2, Fc fusion, Avi-Tag, (Human) HiP™
$320
71270 50 µg CD2, Fc fusion, Biotin-labeled (Human) HiP™
$420
79557-H 2 vials CD22 CHO Recombinant Cell Line (High Expression)
$5,500
79557-M 2 vials CD22 CHO Recombinant Cell Line (Medium Expression)
$5,500
79464 100 μg CD22, Fc-fusion, Avi-Tag HiP™
$315
79466 50 μg CD22, Fc-fusion, Avi-Tag, Biotin-labeled HiP™
$420
71252 100 µg CD226, Fc fusion (Human) HiP™
$310
71253 50 µg CD226, Fc fusion, Biotin-labeled (Human) HiP™
$420
72051 384 reactions CD226:CD112 Homogeneous Assay Kit
$325
72052 384 reactions CD226:CD155 Homogeneous Assay Kit
$325
72305 100 μg CD244, Fc Fusion (IgG1), Avi-Tag (Human)
$320
72306 50 μg CD244, Fc Fusion (IgG1), Biotin-Labeled (Human)
$420
60624 2 vials CD27 CHO-K1 Stable Recombinant Cell Line
$3,850
79107 50 μg CD27(Mouse), Fc-Fusion (Human), Avi-Tag, Biotin
$420
71176 100 µg CD27, Fc fusion (Human)
$310
79067 100 μg CD27, Fc-Fusion (IgG1), Avi-Tag (Mouse) HiP™
$310
79509 2 vials CD27/NF-kB Reporter-Jurkat Recombinant Cell Line
$8,000

Items 101 to 125 of 464 total

per page
Page:
  1. 3
  2. 4
  3. 5
  4. 6
  5. 7